Top Tweets for #Spimaco
#SPIMACO Begins Procedures to List Al Qassim Medical Services on Nomu https://t.co/FlwdGayR8R
$NWBO #DCVax #SPIMACO #RGMBS2026 #SaudiVision2030
𝗧𝗵𝗲 𝗦𝗮𝘂𝗱𝗶 𝗔𝗿𝗮𝗯𝗶𝗮 𝘀𝘁𝗼𝗿𝘆 𝗶𝘀 𝗻𝗼𝘄 𝗳𝗮𝗿 𝗯𝗶𝗴𝗴𝗲𝗿 𝘁𝗵𝗮𝗻 𝗮 𝗱𝗶𝘀𝘁𝗿𝗶𝗯𝘂𝘁𝗶𝗼𝗻 𝗮𝗴𝗿𝗲𝗲𝗺𝗲𝗻𝘁.
The chronology is becoming impossible to ignore.
𝗔𝘂𝗴𝘂𝘀𝘁 𝟱: The Saudi FDA issues NADR, a new regulatory framework specifically designed to accelerate drugs and 𝗯𝗶𝗼𝗹𝗼𝗴𝗶𝗰𝘀 for rare, serious and life-threatening diseases.
𝗔𝘂𝗴𝘂𝘀𝘁 𝟲: Northwest Biotherapeutics and SPIMACO announce an MOU covering 𝗦𝗙𝗗𝗔 𝗮𝗽𝗽𝗿𝗼𝘃𝗮𝗹, 𝗰𝗼𝗺𝗺𝗲𝗿𝗰𝗶𝗮𝗹𝗶𝘇𝗮𝘁𝗶𝗼𝗻, 𝘀𝘂𝗽𝗽𝗹𝘆, 𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆 𝘁𝗿𝗮𝗻𝘀𝗳𝗲𝗿 𝗮𝗻𝗱 𝗹𝗼𝗰𝗮𝗹𝗶𝘇𝗲𝗱 𝗺𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴 𝗼𝗳 𝗗𝗖𝗩𝗮𝘅-𝗟 𝗶𝗻 𝗦𝗮𝘂𝗱𝗶 𝗔𝗿𝗮𝗯𝗶𝗮.
Not just sales.
Not just distribution.
𝗥𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝗮𝗰𝗰𝗲𝘀𝘀.
𝗧𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆 𝘁𝗿𝗮𝗻𝘀𝗳𝗲𝗿.
𝗠𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴.
𝗟𝗼𝗰𝗮𝗹𝗶𝘇𝗮𝘁𝗶𝗼𝗻.
𝗥𝗲𝗴𝗶𝗼𝗻𝗮𝗹 𝗲𝘅𝗽𝗮𝗻𝘀𝗶𝗼𝗻.
And SPIMACO is expected to work directly with the SFDA.
Now look at what the new NADR framework provides:
• 𝗣𝗿𝗶𝗼𝗿𝗶𝘁𝘆 𝗿𝗲𝘃𝗶𝗲𝘄
• 𝗥𝗼𝗹𝗹𝗶𝗻𝗴 𝘀𝘂𝗯𝗺𝗶𝘀𝘀𝗶𝗼𝗻𝘀
• 𝗖𝗼𝗻𝗱𝗶𝘁𝗶𝗼𝗻𝗮𝗹 𝗮𝗽𝗽𝗿𝗼𝘃𝗮𝗹
• Flexible, risk-based 𝗖𝗠𝗖 requirements
• Accelerated manufacturing-site pathways
• Flexible clinical-evidence requirements
• 𝗘𝘅𝘁𝗲𝗿𝗻𝗮𝗹 𝗰𝗼𝗺𝗽𝗮𝗿𝗮𝘁𝗼𝗿𝘀 when concurrent controls are not feasible
• Explicit recognition of 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺 𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆
That last point matters enormously.
𝗗𝗖𝗩𝗮𝘅 𝗶𝘀 𝗮 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.
DCVax-L is being developed first in glioblastoma, but the underlying dendritic-cell technology is not inherently confined to one tumor type. The NWBO-SPIMACO agreement itself contemplates expansion into additional indications and additional GCC markets.
GBM also falls well within the prevalence range ordinarily associated with rare disease.
Then comes the manufacturing piece.
Saudi Arabia’s conventional Verification/Abridged pathways exclude human advanced-therapy medicinal products. NADR creates a separate regulatory framework for rare-disease drugs and biologics with substantially greater flexibility around evidence, CMC and manufacturing.
And the framework specifically accommodates qualifying manufacturing sites in countries including the 𝗨𝗻𝗶𝘁𝗲𝗱 𝗞𝗶𝗻𝗴𝗱𝗼𝗺.
Where is NWBO’s established cell-therapy manufacturing operation?
𝗦𝗮𝘄𝘀𝘁𝗼𝗻, 𝗨𝗻𝗶𝘁𝗲𝗱 𝗞𝗶𝗻𝗴𝗱𝗼𝗺.
Now put it all together:
𝗡𝗲𝘄 𝗿𝗮𝗿𝗲-𝗱𝗶𝘀𝗲𝗮𝘀𝗲 𝗽𝗮𝘁𝗵𝘄𝗮𝘆: in place.
𝗕𝗶𝗼𝗹𝗼𝗴𝗶𝗰𝘀: included.
𝗘𝘅𝘁𝗲𝗿𝗻𝗮𝗹 𝗰𝗼𝗺𝗽𝗮𝗿𝗮𝘁𝗼𝗿𝘀: contemplated.
𝗣𝗹𝗮𝘁𝗳𝗼𝗿𝗺 𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆: explicitly recognized.
𝗖𝗠𝗖 𝗳𝗹𝗲𝘅𝗶𝗯𝗶𝗹𝗶𝘁𝘆: built in.
𝗨𝗞 𝗺𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴: accommodated.
𝗦𝗣𝗜𝗠𝗔𝗖𝗢: positioned to interface with the SFDA.
𝗗𝗖𝗩𝗮𝘅-𝗟 𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆 𝘁𝗿𝗮𝗻𝘀𝗳𝗲𝗿: contemplated.
𝗦𝗮𝘂𝗱𝗶 𝗺𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴: contemplated.
𝗘𝘅𝗽𝗮𝗻𝘀𝗶𝗼𝗻 𝘁𝗼 𝗮𝗱𝗱𝗶𝘁𝗶𝗼𝗻𝗮𝗹 𝗶𝗻𝗱𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀 𝗮𝗻𝗱 𝗚𝗖𝗖 𝗺𝗮𝗿𝗸𝗲𝘁𝘀: contemplated.
And now SPIMACO’s Vice Chairman and Managing Director, Prof. Ahmed Aljedai, is standing onstage at #RGMBS2026 discussing 𝗯𝗶𝗼𝗹𝗼𝗴𝗶𝗰𝘀 𝗹𝗼𝗰𝗮𝗹𝗶𝘇𝗮𝘁𝗶𝗼𝗻 in Saudi Arabia and emphasizing:
𝗟𝗼𝗰𝗮𝗹𝗶𝘇𝗮𝘁𝗶𝗼𝗻.
𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝘀𝗵𝗶𝗽𝘀.
𝗧𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆 𝘁𝗿𝗮𝗻𝘀𝗳𝗲𝗿.
Those are not incidental themes.
𝗧𝗵𝗲𝘆 𝗮𝗿𝗲 𝘁𝗵𝗲 𝘀𝗮𝗺𝗲 𝗽𝗶𝗹𝗹𝗮𝗿𝘀 𝗯𝘂𝗶𝗹𝘁 𝗶𝗻𝘁𝗼 𝘁𝗵𝗲 𝗡𝗪𝗕𝗢-𝗦𝗣𝗜𝗠𝗔𝗖𝗢 𝗠𝗢𝗨.
https://t.co/XhV58d6LL7
The larger picture is becoming clear.
Saudi Arabia is building the 𝗿𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝗽𝗮𝘁𝗵𝘄𝗮𝘆, 𝗺𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴 𝗶𝗻𝗳𝗿𝗮𝘀𝘁𝗿𝘂𝗰𝘁𝘂𝗿𝗲, 𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆-𝘁𝗿𝗮𝗻𝘀𝗳𝗲𝗿 𝗰𝗮𝗽𝗮𝗰𝗶𝘁𝘆 𝗮𝗻𝗱 𝗰𝗼𝗺𝗺𝗲𝗿𝗰𝗶𝗮𝗹 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝘀𝗵𝗶𝗽𝘀 required to become a regional biotechnology hub.
SPIMACO is executing that strategy.
And 𝗗𝗖𝗩𝗮𝘅-𝗟 𝗶𝘀 𝗮𝗹𝗿𝗲𝗮𝗱𝘆 𝗽𝗮𝗿𝘁 𝗼𝗳 𝗶𝘁.
No public announcement yet establishes that DCVax-L has received NADR designation or SFDA approval.
But the alignment is now extraordinarily specific:
𝗧𝗵𝗲 𝗿𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝗽𝗮𝘁𝗵𝘄𝗮𝘆 𝗳𝗶𝘁𝘀.
𝗧𝗵𝗲 𝗺𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴 𝗽𝗮𝘁𝗵𝘄𝗮𝘆 𝗳𝗶𝘁𝘀.
𝗧𝗵𝗲 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺 𝗺𝗼𝗱𝗲𝗹 𝗳𝗶𝘁𝘀.
𝗧𝗵𝗲 𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆-𝘁𝗿𝗮𝗻𝘀𝗳𝗲𝗿 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝘆 𝗳𝗶𝘁𝘀.
𝗧𝗵𝗲 𝗽𝗮𝗿𝘁𝗻𝗲𝗿 𝗳𝗶𝘁𝘀.
𝗔𝗻𝗱 𝗗𝗖𝗩𝗮𝘅-𝗟 𝗶𝘀 𝗮𝗹𝗿𝗲𝗮𝗱𝘆 𝗻𝗮𝗺𝗲𝗱 𝗶𝗻 𝘁𝗵𝗲 𝗽𝗹𝗮𝗻.
𝗧𝗵𝗶𝘀 𝗶𝘀 𝗻𝗼𝘁 𝗷𝘂𝘀𝘁 𝗮 𝗦𝗮𝘂𝗱𝗶 𝗰𝗼𝗺𝗺𝗲𝗿𝗰𝗶𝗮𝗹𝗶𝘇𝗮𝘁𝗶𝗼𝗻 𝘀𝘁𝗼𝗿𝘆.
𝗧𝗵𝗲 𝗶𝗻𝗳𝗿𝗮𝘀𝘁𝗿𝘂𝗰𝘁𝘂𝗿𝗲 𝗶𝘀 𝗯𝗲𝗶𝗻𝗴 𝗯𝘂𝗶𝗹𝘁 𝗳𝗼𝗿 𝗮 𝗦𝗮𝘂𝗱𝗶-𝗯𝗮𝘀𝗲𝗱 𝗗𝗖𝗩𝗮𝘅 𝗿𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆, 𝗺𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴 𝗮𝗻𝗱 𝗿𝗲𝗴𝗶𝗼𝗻𝗮𝗹 𝗲𝘅𝗽𝗮𝗻𝘀𝗶𝗼𝗻 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.
$nwbo @alphavestcap
https://t.co/lkXcXpLg17
https://t.co/PuZnVPdY3r
https://t.co/ezGVFYCSId
https://t.co/ll0Wja07oV
https://t.co/iBMJqIrcy2
"#SPIMACO concluded its participation as a Platinum Sponsor at hashtag#RGMBS2026, reflecting its strategic direction toward advanced biotechnology and its commitment to turning promising opportunities into practical steps that contribute to achieving the objectives of the National Biotechnology Strategy, localizing advanced technologies, and transferring knowledge."
We aspire to translate this direction into actionable partnerships and initiatives that contribute to building an advanced biotechnology ecosystem, advancing the future of healthcare, and achieving hashtag#MedicalBiotechExcellence in the Kingdom.
$NWBO
The potential in DCVax technologies that SPIMACO recognized is significant — it could be what determines how many shares the Saudi sovereign funds decide to acquire, and at what price. If SPIMACO saw potential in combining the DC vaccine with the influenza and pneumococcal vaccines to treat cancer, and Saudi Arabia decided to produce those vaccines at its new 42,000 m² vaccine manufacturing facility, that would be truly exciting!
https://t.co/z7wouetnEi
Linda Powers, the Company’s CEO, commented: “We are excited to join forces with SPIMACO as a leader in Saudi Arabia’s building of a major global biotechnology hub. SPIMACO has been developing state-of-the-art facilities and acquiring state-of-the-art technologies for this hub. We are gratified that SPIMACO sees the important potential of DCVax technologies, and we look forward to contributing to these developments.”
Randomized Phase I/II Pilot Study of the Immunogenicity of Cyclophosphamide With Peptide Pulsed Mature Dendritic Cells for Patients With Previously Treated Ovarian Epithelial or Primary Peritoneal Carcinoma
https://t.co/Hxz9YanNNn
•Arm-1: Trivalent killed influenza vaccine + Prevnar + DC-Ova
•Arm-2: Trivalent killed influenza vaccine + Prevnar + DC-Ova + Cyclophosphamide
Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission
https://t.co/QsORpjrx8A
https://t.co/qpOyoccN0M
With an investment of approximately USD 133 million (SAR 500 million), the project spans 42,000 m² and will employ approximately 150 people upon operationalization. Production will include influenza, COVID-19, pneumococcal, meningitis, and rotavirus vaccines, supporting national immunisation programs and export plans.
https://t.co/7tZrV3fEWO
https://t.co/HCJyNr7avW
With 80% of construction work completed, the Vaccine Industrial Company project is entering its final stages, paving the way for production to begin next year.
A significant milestone in localizing vaccine manufacturing and building sustainable national capabilities that strengthen the Kingdom’s pharmaceutical security.
$NWBO
https://t.co/T9mYsXGAPz
#SPIMACO concluded its participation as a Platinum Sponsor at #RGMBS2026, reflecting its strategic direction toward advanced biotechnology and its commitment to turning promising opportunities into practical steps that contribute to achieving the objectives of the National Biotechnology Strategy, localizing advanced technologies, and transferring knowledge. We aspire to translate this direction into actionable partnerships and initiatives that contribute to building an advanced biotechnology ecosystem, advancing the future of healthcare, and achieving #MedicalBiotechExcellence in the Kingdom.
#ShilpaBiologicals and #SPIMACO Bio sign strategic license agreement for PD-1 Biosimilar for MENA market - https://t.co/NWcr7f3fzT | #pharma #pharmanews #healthtech #pharmatech
$NWBO
The MOU between SPIMACO and the Pharmaceutical Scientists Group should be about R&D on pre-clinical and clinical readiness!
https://t.co/MGHWIbJVCv
We are pleased to announce that #SPIMACO has signed a Memorandum of Understanding with the Pharmaceutical Scientists Group, aimed at supporting #research and #innovation activities in the pharmaceutical industry, and enhancing collaboration and knowledge exchange to develop advanced therapeutic solutions in the Kingdom.
On this occasion, Dr. Hajed Bin Hajed Hashan, Executive Director of Scientific Affairs and Business Development at SPIMACO, stated:
“This partnership represents an important step toward advancing scientific research and fostering innovation, strengthening our capabilities to deliver pharmaceutical products that meet patients’ needs and contribute to the progress of the pharmaceutical industry in the Kingdom.”
Dr. Alia Alshammari , Chairperson of the Pharmaceutical Scientists Group, expressed her appreciation for this collaboration, saying:
“Our partnership with SPIMACO sets a remarkable example of collaboration between scientific expertise and the industrial sector, empowering research and innovation to advance pharmaceutical development and support the healthcare ecosystem in the Kingdom.”
$NWBO
https://t.co/KmCkZaHVph
As part of the implementation of our cooperation agreement with Boston Oncology Arabia, #SPIMACO is pleased to announce a strategic step to support local manufacturing and advance innovation in the field of specialty #medicines in #SaudiArabia, through the technology transfer and local production of four innovative oral oncology products at our high-potency drug manufacturing facility.
This partnership reflects SPIMACO’s commitment to delivering innovative and safe therapeutic solutions for patients in the Kingdom. The first phase will focus on transferring the technology for the four oncology products, followed by the second phase, which involves starting local production at our advanced facilities. This initiative is part of our strategic vision to strengthen national capabilities in pharmaceutical manufacturing, with the possibility of expanding the product portfolio in the future to include additional oncology medicines.
https://t.co/5SviSkGeG9
SPIMACO had a deal with Boston Oncology Arabia about locally manufacturing four oral oncology drugs. What could be the four possible oral oncology drugs? Were the four drugs tested in clinical trials in combination with DC cancer vaccine?
I suppose given the fact that DC cancer vaccine is probably totally new to SPIMACO or Saudi Arabia government, the best and most efficient way for them to fulfill their ambitions in biotechnology should be: LP gives them the shopping list and they will do shopping!
Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer
https://t.co/Pp0Ued354S
Sipuleucel-T + Abiraterone
Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)
https://t.co/ImYmUyIozP
DC vaccine + Lenalidomide
Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma (Pawel Kalinski)
https://t.co/n18eI0fb3W
αDC1 + Dasatinib
Autologous Dendritic Cell Vaccine in Kidney Cancer (Pawel Kalinski)
https://t.co/fwJckh6SP9
αDC1 + Cabozantinib
Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal Cancer (CombiCoR-Vax)
https://t.co/oNks8Vn0um
Pembrolizumab + DC vaccine + Trifluridine/Tipiracil + Bevacizumab
$NWBO
SPIMACO has been busy!
https://t.co/MGHWIbJVCv
We are pleased to announce that #SPIMACO has signed a Memorandum of Understanding with the Pharmaceutical Scientists Group, aimed at supporting #research and #innovation activities in the pharmaceutical industry, and enhancing collaboration and knowledge exchange to develop advanced therapeutic solutions in the Kingdom.
On this occasion, Dr. Hajed Bin Hajed Hashan, Executive Director of Scientific Affairs and Business Development at SPIMACO, stated:
“This partnership represents an important step toward advancing scientific research and fostering innovation, strengthening our capabilities to deliver pharmaceutical products that meet patients’ needs and contribute to the progress of the pharmaceutical industry in the Kingdom.”
Dr. Alia Alshammari , Chairperson of the Pharmaceutical Scientists Group, expressed her appreciation for this collaboration, saying:
“Our partnership with SPIMACO sets a remarkable example of collaboration between scientific expertise and the industrial sector, empowering research and innovation to advance pharmaceutical development and support the healthcare ecosystem in the Kingdom.”
$NWBO
Prof. Ahmed Aljedai's interview with Harvard Business Review Arabia.
Maybe some longs know the language.
https://t.co/HKdHRnqnb6
We are pleased to share an exclusive interview with Professor Ahmed Aljedai, Vice Chairman and Managing Director of #SPIMACO, with Harvard Business Review Arabia. The discussion covered the developments in the pharmaceutical industry in the Kingdom, as well as SPIMACO’s strategic direction and its key upcoming projects.
https://t.co/z7wouetnEi
$nwbo @alphavestcap
https://t.co/5hlD5xrPmW
part of the implementation of our cooperation agreement with Boston Oncology Arabia, #SPIMACO is pleased to announce a strategic step to support local manufacturing and advance innovation in the field of specialty #medicines in #SaudiArabia, through the technology transfer and local production of four innovative oral oncology products at our high-potency drug manufacturing facility.
This partnership reflects SPIMACO’s commitment to delivering innovative and safe therapeutic solutions for patients in the Kingdom. The first phase will focus on transferring the technology for the four oncology products, followed by the second phase, which involves starting local production at our advanced facilities. This initiative is part of our strategic vision to strengthen national capabilities in pharmaceutical manufacturing, with the possibility of expanding the product portfolio in the future to include additional oncology medicines.
This step extends SPIMACO’s efforts to enhance national self-sufficiency in pharmaceutical production and solidifies our position as a leading partner in developing the Kingdom’s pharmaceutical sector.
On this occasion, Prof. Ahmed Aljedai, Vice Chairman and Managing Director of SPIMACO, stated:
"At SPIMACO, we believe that technology transfer and the localization of advanced pharmaceutical industries are key to building a sustainable healthcare ecosystem that aligns with Saudi Arabia’s Vision 2030. This agreement represents an important step in developing national capabilities for local manufacturing of oncology medicines, supporting pharmaceutical security, and providing innovative and safe treatment options for patients in the Kingdom and the region."
$NWBO
SFDA issued biosimilar guidelines last month — bad news for Big Pharma?
I suspect the MOU just shredded the net Merck has spent the past five years knitting.
https://t.co/yu02yJ3GSO
#dcvax $nwbo #gbm
In #60SecondsinHealth, we take a closer look at #SPIMACO and how its integrated capabilities across manufacturing, distribution, and pharmaceutical specialties help ensure supply.... https://t.co/mDWOSGgvWT
https://t.co/LxqEWGDA1I
#نبض_السوق
#نبض_النتائج
#نبض_القوائم
.
نظرة مختصرة على الهوامش والعوائد المحققة في شركات الصناعات الدوائية المدرجة في #تاسي لعام 2025م
2070 #الدوائية #Spimaco
4015 #جمجوم_فارما #Jamjoom_Pharmaceuticals
4016 #أفالون_فارما #Avalon_Pharma
Khalid AlKhattaf, CEO #SPIMACO, highlights Saudi Arabia's commitment to healthcare regulations, positioning KSA as a regional benchmark. Through collaboration & investments, high-tech labor from Asia & Europe can be leveraged for competitive advantage. #ArabChinaConference
#SPIMACO Taps Google Cloud for Latest Digital Transformation in #Pharmaceuticals Sector in The Kingdom of Saudi Arabia https://t.co/JTmJgxYvSY #googlecloud #saudiarabia #sap #infrastructure #saudipharmaceuticalindustriesandmedicalappliancescorporation
SPIMACO Taps Google Cloud for Latest Digital Transformation in Pharmaceuticals Sector in The Kingdom of Saudi Arabia
https://t.co/JTmJgxZ3Iw
#GoogleCloud #SPIMACO #SaudiArabia #KSA
#SPIMACO Taps Google Cloud for Latest Digital Transformation in #Pharmaceuticals Sector in The Kingdom of Saudi Arabia https://t.co/JTmJgxZ3Iw #saudipharmaceuticalindustriesandmedicalappliancescorporation #infrastructure #googlecloud #sap #saudiarabia
Last Seen Hashtags on Sotwe
송형준도안
Seen from United States
anxiouspanda
Seen from Germany
喷奶
ميقا_حصريات
Seen from Pakistan
catrinatoychica
Seen from United States
jvcheer
Seen from United States
سوالب_بغداد
nolimit son filter:native_video
Seen from Argentina
dreamsandnighmares
Seen from United States
千本ゑんま堂大念佛狂言
Seen from United States
Most Popular Users
Elon Musk 
@elonmusk
241.7M followers
Barack Obama
@barackobama
119M followers
Cristiano Ronaldo
@cristiano
114.3M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.2M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.4M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
89.9M followers
Taylor Swift
@taylorswift13
83.9M followers
Lady Gaga
@ladygaga
75.4M followers
Virat Kohli
@imvkohli
73.3M followers
Kim Kardashian
@kimkardashian
70.9M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66.3M followers
Bill Gates
@billgates
65.1M followers
Selena Gomez
@selenagomez
63M followers
The Ellen Show
@theellenshow
62.3M followers
CNN
@cnn
61.8M followers
X
@x
60.7M followers